Scott MD - Pacira Pharmaceuticals Sr. VP of Strategy and Corporate Devel.
| PCRX Stock | USD 26.05 0.28 1.06% |
SVP
Scott MD is Sr. VP of Strategy and Corporate Devel. of Pacira Pharmaceuticals
| Address | 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609 |
| Phone | 813 553 6680 |
| Web | https://www.pacira.com |
Pacira Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0335 % which means that it generated a profit of $0.0335 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.051 %, meaning that it created $0.051 on every $100 dollars invested by stockholders. Pacira Pharmaceuticals' management efficiency ratios could be used to measure how well Pacira Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.05 in 2024. Return On Capital Employed is likely to rise to 0.06 in 2024. At this time, Pacira Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.1 B in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Management Performance
| Return On Equity | 0.051 | ||||
| Return On Asset | 0.0335 |
Pacira Pharmaceuticals Leadership Team
Elected by the shareholders, the Pacira Pharmaceuticals' board of directors comprises two types of representatives: Pacira Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pacira. The board's role is to monitor Pacira Pharmaceuticals' management team and ensure that shareholders' interests are well served. Pacira Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pacira Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gary Pace, Independent Director | ||
| Daryl Gaugler, Chief Officer | ||
| Mark Kronenfeld, Independent Director | ||
| Charles Laranjeira, Chief Technical Officer | ||
| John Longenecker, Independent Director | ||
| Mark Froimson, Director | ||
| Scott MD, Sr. VP of Strategy and Corporate Devel. | ||
| Laura Brege, Independent Director | ||
| James Scibetta, Pres and CFO | ||
| Dennis McLoughlin, Chief Commercial Officer | ||
| David Stack, Chairman and CEO | ||
| Richard Scranton, Chief Scientific Officer | ||
| Susan Mesco, IR Contact Officer | ||
| Roy Winston, Chief Clinical Officer | ||
| Jonathan MD, Chief Officer | ||
| Lauren Riker, Principal Finance | ||
| Frank Lee, CEO Director | ||
| Yvonne Greenstreet, Independent Director | ||
| Richard Kahr, Vice Resources | ||
| James Jones, Senior Vice President Chief Medical Officer | ||
| Charles Reinhart, CFO | ||
| Dennis Winger, Independent Director | ||
| Robert Weiland, Chief Commercial Officer | ||
| DO Ellis, Chief Officer | ||
| Paul Hastings, Independent Director | ||
| III CPA, Chief Officer | ||
| Max Reinhardt, Pres World | ||
| Andreas Wicki, Independent Director | ||
| Scott Braunstein, Senior Vice President - Strategy and Corporate Development | ||
| Kristen JD, Chief Secretary | ||
| Kristen Williams, Chief Administrative Officer, General Counsel, Secretary | ||
| Roy MD, Chief Officer | ||
| Esq III, Chief Officer |
Pacira Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pacira Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.051 | ||||
| Return On Asset | 0.0335 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 1.53 B | ||||
| Shares Outstanding | 46.52 M | ||||
| Shares Owned By Insiders | 1.26 % | ||||
| Shares Owned By Institutions | 98.74 % | ||||
| Number Of Shares Shorted | 3.45 M | ||||
| Price To Earning | 14.34 X |
Pacira Pharmaceuticals Investors Sentiment
The influence of Pacira Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Pacira. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Pacira Pharmaceuticals' public news can be used to forecast risks associated with an investment in Pacira. The trend in average sentiment can be used to explain how an investor holding Pacira can time the market purely based on public headlines and social activities around Pacira Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Pacira Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pacira Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Pacira Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Pacira Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pacira Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pacira Pharmaceuticals' short interest history, or implied volatility extrapolated from Pacira Pharmaceuticals options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pacira Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Pacira Stock analysis
When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.291 | Earnings Share 0.89 | Revenue Per Share 14.603 | Quarterly Revenue Growth 0.054 | Return On Assets 0.0335 |
The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.